Super-potent human antibodies protect against COVID-19 in animal tests
On Jun. 15, 2020, a team led by Scripps Research discovered antibodies in the blood of recovered COVID-19…
Catalent announced agreement with AstraZeneca to manufacture COVID-19 vaccine candidate
On Jun. 15, 2020, Catalent announced that it will provide vial filling and packaging capacity to AstraZeneca at…
Immunic announced first patients dosed in its phase 2, CALVID-1 clinical trial of IMU-838 in COVID-19
On Jun. 15, 2020, Immunic announced dosing of the first patients in its phase 2, CALVID-1 clinical trial…
Mutated coronavirus shows significant boost in infectivity
On Jun. 12, 2020, a tiny genetic mutation in the SARS coronavirus 2 variant circulating throughout Europe and…
CIRM board approved two additional COVID-19 projects
On Jun. 12, 2020, the California Institute for Regenerative Medicine (CIRM) awarded $349,999 to Dr. Vaithilingaraja Arumugaswami at…
Cue Health received FDA EUA for Its rapid, portable, molecular point-of-care COVID-19 test
On Jun. 12, 2020, Cue Health announced that it had received Emergency Use Authorization from the U.S. Food…
Biotechnology | CDC | HIV | Therapeutics
The FDA approved drug to treat infants and children with HIV
On Jun. 12, 2020, the U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Tivicay (dolutegravir) tablets and…
ViiV Healthcare announced FDA approval of the first-ever dispersible tablet formulation of dolutegravir for children living with HIV
On Jun. 12, 2020, ViiV Healthcare, a GSK company, with Pfizer and Shionogi Limited, announced the FDA had…
Biotechnology | COVID-19 | Diagnostics | FDA
InBios received FDA Emergency Use Authorization for COVID-19 antibody test
On Jun. 11, 2020, InBios announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…
Atossa Therapeutics announced availability of manuscript on results from in vitro testing of COVID-19 drug
On Jun. 11, 2020, Atossa Therapeutics announced that the manuscript of the results from in vitro testing of…
NIH researchers identified key genomic features that could differentiate SARS-CoV-2 from other coronaviruses that cause less severe disease
On Jun. 11, 2020, a team of researchers from the National Library of Medicine identified genomic features of…
NIH scientists developed blood test to help improve liver cancer screening
On Jun. 11, 2020, scientists announced the development of a new test that can help identify people who…
Brain cells can harbor and spread HIV virus to the body
On Jun. 11, 2020, researchers have found that astrocytes, a type of brain cell can harbor HIV and…
Emergent BioSolutions signed agreement to be US manufacturing partner for AstraZenecaﾒs COVID-19 vaccine candidate
On Jun. 11, 2020, Emergent BioSolutions announced deployment of its molecule-to-market contract development and manufacturing (CDMO) services to…
Innovation Pharma collaborated with regional biocontainment lab on grant application to research Brilacidin as pan-Coronavirus therapeutic
On Jun. 11, 2020, Innovation Pharma announced the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL)…
Two science publications highlight potential of REGN-COV2 anti-viral antibody cocktail to protect against SARS-CoV-2 escape mutants
On Jun. 11, 2020, Regeneron announced that Science had accepted for publication two papers describing the creation of…
The FDA authorized first next generation sequence test for diagnosing COVID-19
On Jun. 10, 2020, the FDA issued an emergency use authorization (EUA) to Illumina for the first COVID-19…
Catalent partnered with Spicona to develop COVID-19 vaccine candidate using GPEx cell line development platform
On Jun. 10, 2020, Catalent announced that it had signed an agreement with Spicona to develop a virus-like…
Disease | Therapeutics | WHO
No link between two ongoing Ebola outbreaks in the Democratic Republic of the Congo
On Jun. 9, 2020, new genetic sequence analysis by the Democratic Republic of the Congo’s (DRC) National Institute…
Up to 45 percent of SARS-CoV-2 infections may be asymptomatic, new analysis found
On Jun. 9, 2020, a Scripps research analysis of public datasets on asymptomatic infections, an extraordinary percentage of…
Immunic announced FDA allowance of its phase 2, CALVID-1 clinical trial of IMU-838 in COVID-19
On Jun. 9, 2020, Immunic announced receipt of regulatory allowance from the FDA to initiate its phase 2,…
Emergency COVID-19 measures prevented more than 500 million infections
On Jun. 8, 2020, Emergency health measures implemented in six major countries have ﾓsignificantly and substantially slowedﾔ the…
FibroGen announced first patient enrolled in Pamrevlumab clinical trial in patients hospitalized in Italy with severe COVID-19
On Jun. 8, 2020, FibroGen announced the initiation of an open-label, randomized, parallel-arm study investigating the efficacy and…
Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients
On Jun. 5, 2020, results were published in Science Immunology showed that Calquence (acalabrutinib), a Brutonﾒs tyrosine kinase…
Sorrento announced COVIDTRAP(STI-4398) demonstrated in preclinical studies its ability to completely inhibit SARS-CoV-2 viral infection In vitro
On Jun. 5, 2020, Sorrento announced it had completed a preclinical batch of the STI-4398 (COVIDTRAP) protein and…
HPV vaccine manufacturers commited to provide enough supply to immunise at least 84 million girls in Gavi countries
On Jun. 4, 2020, vaccine manufacturers MSD, GSK, Innovax, Serum Institute of India and Walvax pledged to ramp…
COVID-19 | Diagnostics | NIH
HHS announced new laboratory data reporting guidance for COVID-19 testing
On Jun. 4, 2020, the U.S. Department of Health and Human Services (HHS) announced new Guidance that specified…
HPV vaccine manufacturers committed to immunise at least 84 million girls in Gavi countries
On Jun. 4, 2020, vaccine manufacturers MSD, GSK, Innovax, Serum Institute of India (SII) and Walvax pledged to…
Introduction and spread of SARS-CoV-2 in the greater Boston area
On Jun. 4, 2020, data from the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and the…
CEPI granted $141 million to consortium of Bharat Biotech and IVI to advance development of Chikungunya vaccine in collaboration with Ind-CEPI
On Jun. 3, 2020, CEPI, the Coalition for Epidemic Preparedness Innovations, in collaboration with Ind-CEPI, announced a new…